Mankind Pharma has received the licence to manufacture and market oral 2-deoxy-D-glucose (2-DG) from Defence Research and Development Organisation (DRDO), the company said on Thursday.
The drug is used for the treatment of COVID-19. In a statement, the company said, 2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior.
The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy's Laboratories.
It will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added. The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct